Keymed Biosciences Inc.
Research Keymed Biosciences Inc. (2162.HK) on Bullrun: market cap HKD 24.14B, P/E 27.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2162.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 24.14B
- P/E27.8
- Financial periodFY2025
- RevenueCNY 716.31M
- Revenue growth67.3%
- Net income-CNY 522.64M
- Free cash flow-CNY 1.05B
- Gross margin87.7%
Valuation Snapshot
latest market cap is HKD 24.14B; P/E is 27.8.
Peer valuation comparison
Latest P/E is 27.78x versus a Healthcare sector median of 21.69x (28.1% above).
Latest P/E is 27.78x versus a China median of 16.26x (70.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 716.31M | -CNY 522.64M | -CNY 1.05B | 87.7% | -1.91 | CNY 503.35M | CNY 788.54M | CNY 2.77B |
| FY2024 | CNY 428.12M | -CNY 515.24M | -CNY 1.00B | 97.2% | -1.97 | CNY 418.41M | CNY 753.24M | CNY 2.47B |
| FY2023 | CNY 354.10M | -CNY 359.36M | -CNY 686.23M | 89.6% | -1.37 | CNY 851.03M | CNY 418.71M | CNY 2.99B |
| FY2022 | CNY 100.06M | -CNY 308.12M | -CNY 681.48M | 97.4% | -1.18 | CNY 604.07M | CNY 121.97M | CNY 3.34B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 24.14B | 27.8 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Keymed Biosciences Inc.
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Keymed Biosciences Inc.'s market cap?
Keymed Biosciences Inc.'s market capitalization is HKD 24.14B.
What is Keymed Biosciences Inc.'s P/E ratio?
Keymed Biosciences Inc.'s price-to-earnings (P/E) ratio is 27.8.
What does Keymed Biosciences Inc. do?
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom.